Medications For Heart Failure Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion

Medications For Heart Failure Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Medications For Heart Failure Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The market size for medications addressing heart failure has experienced robust growth in recent years. Its value is projected to increase from $10.79 billion in 2025 to $11.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be largely attributed to factors such as the rising occurrence of cardiovascular diseases, an aging global demographic, an increase in the incidence of hypertension and diabetes, improved access to vital cardiac medications, and the broadening availability of hospital-based cardiac care.

The market for medications for heart failure is anticipated to experience robust growth in the upcoming years. It is projected to expand to $15.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period can be attributed to an expanding heart failure patient population, increasing acceptance of novel drug classifications, a rising emphasis on personalized cardiovascular therapy, the broadening of outpatient and home-based care approaches, and a stronger focus on preventive cardiology. Significant trends during this period include the rising adoption of combination drug therapies, the expanding use of SGLT2 inhibitors in heart failure treatment, a growing concentration on early diagnosis and long-term disease management, the expansion of evidence-based treatment guidelines, and a heightened emphasis on reducing heart failure hospitalizations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=48752056&type=smp&name=Medications%20For%20Heart%20Failure%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Medications For Heart Failure Market Growth Drivers: What’s Behind The Acceleration?

An escalating incidence of cardiovascular diseases is anticipated to boost the growth of the medications for the heart failure market moving forward. These conditions involve the heart and blood vessels, often leading to severe health events such as heart attacks and strokes. The increase in cardiovascular diseases is primarily fueled by inactive lifestyles that gradually impair heart and vessel health. As the rates of cardiovascular disease climb, the demand for effective treatments expands, encouraging greater investment in heart failure medications. With the condition becoming more widespread, pharmaceutical companies are prioritizing the creation and enhancement of therapies to improve symptom management and patient outcomes. For instance, in September 2024, the Heart Failure Society of America (HFSA), a US-based organization of heart failure experts, reported that approximately 6.7 million Americans aged 20 and older are currently living with heart failure (HF). This number is expected to reach 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Hence, the increasing prevalence of cardiovascular diseases is propelling the expansion of medications for the heart failure market.

Medications For Heart Failure Market Segmentation And Category Overview

The medications for heart failure market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril

2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan

6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin

Medications For Heart Failure Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies within the medication for heart failure market are concentrating on developing sophisticated drugs, such as sodium-glucose cotransporter (SGLT) inhibitors, to facilitate more effective long-term management of heart failure symptoms and associated complications. An SGLT inhibitor is an advanced therapeutic agent that targets glucose reabsorption mechanisms to address heart failure, enhance overall efficiency, and optimize cardiovascular health. For instance, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, introduced Inpefa (sotagliflozin), which gained approval from the Food and Drug Administration (FDA). This once-daily oral tablet is formulated to lessen the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults presenting with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval represents a significant landmark for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to enter the market, offering a new treatment avenue for heart failure patients facing a wide spectrum of conditions.

Medications For Heart Failure Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Hainan Poly Pharm Co Ltd, Lunan Pharmaceutical Group, Mylan Laboratories Inc., JM Laboratories, Lexicon Pharmaceuticals, Pfizer Inc, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Amgen Inc, Otsuka Pharmaceutical Co Ltd

View The Full Medications For Heart Failure Market Report:

https://thebusinessresearchcompany.com/report/medications-for-heart-failure-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Medications For Heart Failure Market Regional Analysis And Top Geography

North America was the largest region in the medications for the heart failure market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model